KR920021134A - 저 용해도 약제로 피복된 비이드 조성물 - Google Patents
저 용해도 약제로 피복된 비이드 조성물 Download PDFInfo
- Publication number
- KR920021134A KR920021134A KR1019920008311A KR920008311A KR920021134A KR 920021134 A KR920021134 A KR 920021134A KR 1019920008311 A KR1019920008311 A KR 1019920008311A KR 920008311 A KR920008311 A KR 920008311A KR 920021134 A KR920021134 A KR 920021134A
- Authority
- KR
- South Korea
- Prior art keywords
- sugar
- weight
- beads
- polyethylene glycol
- polyoxyethylene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (10)
1중량%미만의 수용해도를 갖는 약제 약 1 내지 약 80중량%, 하이드록시프로필 셀룰로즈 및 하이드록시프로필 메틸셀룰로즈로 구성된 군으로 부터 선택된 셀룰로즈 유도체 약 1 내지 약 30중량%, 약 1,000 내지 약 8,000의 분자량을 갖는 폴리에틸렌 글리콜 및 d-α 토코페릴 폴리에틸렌 글리콜 1000 숙시네이트(여기서, 폴리에틸렌 글리콜 성분은 약 1,000의 평균 화학식량을 가짐)로 구성된 군으로부터 선택된 폴리에틸렌 글리콜 또는 그의 유도체 약 1 내지 약 30중량% 및 하기 구조식(I)의 폴리옥시에틸렌-폴리옥시프로필렌-폴리옥시에틸렌 블록 공중합체, 설포부탄디오산 1,4-비스(2-에틸헥실)에스테르 나트륨 염 및 황산 모노도데실 에스테르 나트륨염으로 구성된 군으로부터 선택된 밀랍질(waxy)고형물 약 1 내지 약 30중량%로 필수적으로 이루어진 피복 조성물 약 10 내지 약 300중량%로 피복된 당 또는 당/전분 비이드(bead) :
HO(CH2CH2O)a[CH(CH3)CH2O]b(CH2CH20)aH (I)
상기 식에서, a는 약 79이고, b는 약 28이다.
제1항에 있어서, 1중량%미만의 수용해도를 갖는 약제 약 1 내지 약80중량%, 하이드록시프로필 메틸셀룰로즈 약 1 내지 약 30중량%, 약 1,000 내지 약 8,000의 분자량을 갖는 폴리에틸렌 글리콜 약 1 내지 약 30중량% 및 하기 구조식(I)의 폴리옥시에틸렌-폴리옥시프로필렌-폴리옥시에틸렌 블록 공중합체 약 1 내지 약 30중량% 로 필수적으로 이루어진 피복 조성물 약 10 내지 약 300중량%로 피복된 당 또는 당/전분 비이드 :
HO(CH2CH2O)a[CH(CH3)CH2O]b(CH2CH20)aH (I)
상기 식에서, a는 약 79이고, b는 약 28이다.
제2항에 있어서, 상기 약제가 항안드로젠성 스테로이드인 피복된 당 또는 당/전분 비이드.
제3항에 있어서, 상기 항안드로젠성 스테로이드가 (5α, 17α)-1'-(메틸설포닐)-1' H-프레근-20-이노[3,2-c]피라졸-17-올이고 피복 조성물의 약 40 내지 약 80중량%를 차지하며, 폴리에틸렌 글리콜이 약 3350의 분자량을 가지고 있으며, 하이드로프로필 메틸설룰로주, 폴리에틸렌 글리콜 및 폴리옥시에틸렌-폴리옥시프로필렌-폴리옥시에틸렌 블록 공중합체 각각의 양이 피복 조성물의 약 5 내지 약 15중량%를 차지하는 피복된 당 또는 당/전분 비이드.
제1항에 따른 피복된 당 또는 당/전분 비이드 약 40mg 내지 약 700m으로 충진된 약학적 캡슐.
제4항에 따른 피복된 당 또는 당/전분 비이드 약 40mg 내지 약 700m으로 충진된 약학적 캡슐.
하이드록시프로필 셀룰로즈 또는 하이드록시프로필 메틸셀룰로즈, 폴리에틸렌 글리콜 또는 그의 유도체, 및 밀랍질 고형물을 이들의 혼합중량의 약3내지 약 10배의 물에 가온시키면서 용해하고, 수득된 용액에 약제를 교반하면서 현탁시키고, 수득된 현탁액으로 비이드를 피복한 다음, 수득된 피복 비이드를 건조함을 포함하는, 제1항에 따른 피복된 당 또는 당/전분 비이드의 제조방법.
하이드록시프로필 메틸셀룰로즈, 폴리에틸렌 글리콜 및 폴리옥시에틸렌-폴리옥시프로플렌-폴리옥시에틸렌 블록 공중합체를 이들의 혼합중량의 약 3 내지 약 10배의 물에 가온시키면서 용해하고, 수득된 용액에 약제를 교반하면서 현탁시키고, 수득된 현탁액으로 비이드를 피복한 다음, 수득된 피복 비이드를 건조함을 포함하는, 제2항에 따른 피복된 당 또는 당/전분 비이드의 제조방법.
하이드록시프로필 메틸셀룰로즈, 폴리에틸렌 글리콜 및 폴리옥시에틸렌-폴리옥시프로플렌-폴리옥시에틸렌 블록 공중합체를 이들의 혼합중량의 약 3 내지 약 10배의 물에 가온시키면서 용해하고, 수득된 용액에 약제를 교반하면서 현탁시키고, 수득된 현탁액으로 비이드를 피복한 다음, 수득된 피복 비이드를 건조함을 포함하는, 제3항에 따른 피복된 당 또는 당/전분 비이드의 제조방법.
하이드록시프로필 메틸셀룰로즈, 폴리에틸렌 글리콜 및 폴리옥시에틸렌-폴리옥시프로플렌-폴리옥시에틸렌 블록 공중합체를 이들의 혼합중량의 약 3 내지 약 10배의 물에 가온시키면서 용해하고, 수득된 용액에 약제를 교반하면서 현탁시키고, 수득된 현탁액으로 비이드를 피복한 다음, 수득된 피복 비이드를 건조함을 포함하는, 제4항에 따른 피복된 당 또는 당/전분 비이드의 제조방법.
※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US700968 | 1991-05-16 | ||
US07/700,968 US5223268A (en) | 1991-05-16 | 1991-05-16 | Low solubility drug-coated bead compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
KR920021134A true KR920021134A (ko) | 1992-12-18 |
Family
ID=24815547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920008311A KR920021134A (ko) | 1991-05-16 | 1992-05-16 | 저 용해도 약제로 피복된 비이드 조성물 |
Country Status (13)
Country | Link |
---|---|
US (2) | US5223268A (ko) |
EP (1) | EP0514967A1 (ko) |
JP (1) | JPH05132417A (ko) |
KR (1) | KR920021134A (ko) |
AU (1) | AU1492092A (ko) |
CA (1) | CA2067314A1 (ko) |
FI (1) | FI922234A (ko) |
HU (1) | HUT62461A (ko) |
IE (1) | IE921568A1 (ko) |
IL (1) | IL101884A0 (ko) |
MX (1) | MX9202247A (ko) |
NO (1) | NO921924L (ko) |
NZ (1) | NZ242357A (ko) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW212139B (ko) * | 1991-04-15 | 1993-09-01 | Yamanouchi Pharma Co Ltd | |
US5223268A (en) * | 1991-05-16 | 1993-06-29 | Sterling Drug, Inc. | Low solubility drug-coated bead compositions |
KR100260632B1 (ko) * | 1992-12-28 | 2000-07-01 | 성재갑 | 이식형 소마토트로핀 조성물 |
DK95093D0 (da) * | 1993-08-20 | 1993-08-20 | Novo Nordisk As | Farmaceutisk formulering indeholdende et hormon |
CA2166722A1 (en) * | 1994-05-06 | 1995-11-16 | Manoj L. Maniar | Use of vitamin e tocopheryl derivatives in ophthalmic compositions |
GB9409778D0 (en) | 1994-05-16 | 1994-07-06 | Dumex Ltd As | Compositions |
US5938990A (en) * | 1994-07-01 | 1999-08-17 | Roche Vitamins Inc. | Encapsulation of oleophilic substances and compositions produced thereby |
US5547948A (en) * | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
US5759577A (en) * | 1995-01-17 | 1998-06-02 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
US5573783A (en) * | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
GB2311699B (en) * | 1996-03-29 | 2000-09-20 | Nokia Mobile Phones Ltd | Method and apparatus for digital communication |
US5891469A (en) * | 1997-04-02 | 1999-04-06 | Pharmos Corporation | Solid Coprecipitates for enhanced bioavailability of lipophilic substances |
CA2230748C (en) * | 1997-03-14 | 2010-08-03 | American Home Products Corporation | Rapamycin formulations for oral administration |
EP1137403B1 (en) | 1998-12-11 | 2009-03-11 | Nostrum Pharmaceuticals, Inc. | Sustained release tablet containing hydrocolloid and cellulose ether |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7863331B2 (en) | 1999-07-09 | 2011-01-04 | Ethypharm | Pharmaceutical composition containing fenofibrate and method for the preparation thereof |
FR2795961B1 (fr) * | 1999-07-09 | 2004-05-28 | Ethypharm Lab Prod Ethiques | Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation |
US20060034937A1 (en) * | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7115297B2 (en) * | 2000-02-22 | 2006-10-03 | Suzanne Jaffe Stillman | Nutritionally fortified liquid composition with added value delivery systems/elements/additives |
US8178150B2 (en) | 2000-02-22 | 2012-05-15 | Suzanne Jaffe Stillman | Water containing soluble fiber |
US7892586B2 (en) | 2001-02-22 | 2011-02-22 | Suzanne Jaffe Stillman | Water containing soluble fiber |
US6673373B2 (en) * | 2001-02-01 | 2004-01-06 | Carlsbad Technology Inc. | Antifungal formulation and the methods for manufacturing and using the same |
EP1729595B1 (en) * | 2004-03-04 | 2008-12-10 | Cem Dr. Gökhan | Artificial fruit |
US20080096819A1 (en) * | 2006-05-02 | 2008-04-24 | Allozyne, Inc. | Amino acid substituted molecules |
EP2395099A3 (en) * | 2006-05-02 | 2012-05-16 | Allozyne, Inc. | Amino acid substituted molecules |
CA2707840A1 (en) * | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
AT12800U1 (de) * | 2007-11-05 | 2012-11-15 | Bayer Schering Pharma Ag | Pharmazeutisches Präparat zur Verwendung bei der oralen Kontrazeption von Frauen mit Laktoseintoleranz |
EP2548456B1 (en) | 2008-03-20 | 2015-07-08 | Virun, Inc. | Emulsions including a PEG-derivative of tocopherol |
EP2268274B1 (en) | 2008-03-20 | 2012-05-16 | Virun, Inc. | Vitamin e derivatives and their uses |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
WO2011119228A1 (en) * | 2010-03-23 | 2011-09-29 | Virun, Inc. | Nanoemulsion including sucrose fatty acid ester |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
US20180147215A1 (en) | 2016-11-28 | 2018-05-31 | Lipocine Inc. | Oral testosterone undecanoate therapy |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2966564D1 (en) * | 1978-11-20 | 1984-02-23 | American Home Prod | Therapeutic compositions with enhanced bioavailability and process for their preparation |
US4783337A (en) * | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
GB8414221D0 (en) * | 1984-06-04 | 1984-07-11 | Sterwin Ag | Unit dosage form |
US4684636A (en) * | 1985-06-24 | 1987-08-04 | Sterling Drug Inc. | Antiandrogenic sulfonylsteroidopyrazoles and processes for preparation method of use and compositions thereof |
US4837033A (en) * | 1987-12-22 | 1989-06-06 | Shin-Etsu Chemical Co., Ltd. | Method for the preparation of a coated solid medicament |
US5223268A (en) * | 1991-05-16 | 1993-06-29 | Sterling Drug, Inc. | Low solubility drug-coated bead compositions |
-
1991
- 1991-05-16 US US07/700,968 patent/US5223268A/en not_active Expired - Fee Related
-
1992
- 1992-04-14 NZ NZ242357A patent/NZ242357A/en unknown
- 1992-04-15 AU AU14920/92A patent/AU1492092A/en not_active Abandoned
- 1992-04-27 CA CA002067314A patent/CA2067314A1/en not_active Abandoned
- 1992-05-08 EP EP92201317A patent/EP0514967A1/en not_active Withdrawn
- 1992-05-14 MX MX9202247A patent/MX9202247A/es unknown
- 1992-05-15 FI FI922234A patent/FI922234A/fi not_active Application Discontinuation
- 1992-05-15 HU HU9201623A patent/HUT62461A/hu unknown
- 1992-05-15 NO NO92921924A patent/NO921924L/no unknown
- 1992-05-15 JP JP4123367A patent/JPH05132417A/ja not_active Withdrawn
- 1992-05-15 IL IL101884A patent/IL101884A0/xx unknown
- 1992-05-16 KR KR1019920008311A patent/KR920021134A/ko not_active Application Discontinuation
- 1992-07-01 IE IE156892A patent/IE921568A1/en unknown
-
1993
- 1993-05-12 US US08/060,326 patent/US5340589A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
HUT62461A (en) | 1993-05-28 |
US5340589A (en) | 1994-08-23 |
HU9201623D0 (en) | 1992-08-28 |
IE921568A1 (en) | 1992-11-18 |
EP0514967A1 (en) | 1992-11-25 |
CA2067314A1 (en) | 1992-11-17 |
FI922234A0 (fi) | 1992-05-15 |
NO921924L (no) | 1992-11-17 |
JPH05132417A (ja) | 1993-05-28 |
AU1492092A (en) | 1992-11-19 |
IL101884A0 (en) | 1992-12-30 |
NZ242357A (en) | 1993-06-25 |
FI922234A (fi) | 1992-11-17 |
MX9202247A (es) | 1992-11-01 |
US5223268A (en) | 1993-06-29 |
NO921924D0 (no) | 1992-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920021134A (ko) | 저 용해도 약제로 피복된 비이드 조성물 | |
Phillipps | Structure-activity relationships in steroidal anaesthetics | |
FI84783B (fi) | Foerfarande foer framstaellning av ett farmaceutiskt preparat i enhetsdosform. | |
TWI232752B (en) | Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and composition and pharmaceutical composition comprising the same | |
US4614545A (en) | Hydroxypropyl methyl cellulose thickening agents for organic liquids | |
KR940018086A (ko) | 나노캡슐을 함유하는 제약조성물 | |
US5213811A (en) | Oral sustained-release drug compositions | |
US3883540A (en) | Unsymmetrical esters of N-substituted 1,4-dihydropyridine 3,5-dicarboxylic acid | |
ATE157686T1 (de) | Nassfeste stärkewerkstoffe für die herstellung von giessfolien und thermoplastischen materialien | |
IE42604L (en) | Pharmaceutical preparation in the form of a foil | |
PL101842B1 (pl) | A method of producing the pharmaceutical carrier in the form of foil with built in active agent | |
DK164020B (da) | Fast praeparat af dihydropyridin a samt fremgangsmaade til fremstilling heraf | |
SK287254B6 (sk) | Použitie derivátov benzazepín-N-kyseliny octovej na výrobu farmaceutických prípravkov na liečbu vysokého krvného tlaku | |
PT92168B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo derivados de nucleos de estrogenios para provocar a inibicao da actividade de esteroides sexuais | |
KR950008531A (ko) | 11-벤즈알독심-17β-메톡시-17α-메톡시메틸-에스트라디엔 유도체, 이의 제조방법 및 이를 함유하는 약제 | |
ATE40126T1 (de) | 1,5-benzothiazepinderivate, verfahren zu ihrer herstellung und arzneimittel. | |
KR950011462A (ko) | 호르몬 활성이 저하된 에스트라디올 유도체-알킬화제 결합체, 그의 제조방법, 그의 제조에 유용한 화합물, 및 상기 결합체 또는 에스트라디올 유도체를 함유하는 성장억제조성물 | |
JP2001509487A (ja) | ペプチケミオを含有する薬剤学的組成物 | |
JPH02502379A (ja) | 5‐シアノ‐プロスタサイクリン誘導体のシクロデキストリンクラスレート化合物、および薬剤としてのその使用 | |
EP0468232B1 (en) | Suspending syrups | |
JPH07157431A (ja) | 安定なプロスタグランジンe製剤 | |
PL121664B1 (en) | Process for preparing inclusion compounds of prostacycline and its esters with alkyls of 1 to 4 carbon atoms with cyclodextrinsna i ego alkilovykh ehfirov s 1-4 atomami uglja s ciklogekstrinami | |
Teshima et al. | Hypocholesterolemic effect of 24-methylenecholesterol and 7-cholestenol in the rat | |
SE465751B (sv) | Farmaceutiskt preparat innehaallande co-dergocrin och en kalciumantagonist | |
YAMAHIRA et al. | Lipid-containing oral dosage form: significance of the intragastric metabolism of medium chain triglyceride in relation to the uniformity of drug absorption rate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |